Literature DB >> 20800884

Urinary prostaglandin E₂ was increased in patients with suprapontine brain diseases, and associated with overactive bladder syndrome.

Hiroki Yamauchi1, Hironobu Akino, Hideaki Ito, Yoshitaka Aoki, Tadao Nomura, Osamu Yokoyama.   

Abstract

OBJECTIVE: To investigate the association between the urinary levels of prostaglandins (PGE(2) and PGF(2α)), nerve growth factor (NGF) and substance P, and overactive bladder (OAB) symptoms in patients with suprapontine brain diseases.
MATERIALS AND METHODS: The subjects were 114 patients in the chronic phase of a brain disease and 27 healthy controls with no brain disease or lower urinary tract symptoms (LUTS). The OAB symptoms were assessed with the OAB symptom score and the subjects were then classified into 5 groups: healthy control, patients without LUTS, increased bladder sensation (IBS), OAB dry, and OAB wet. Urinary mediator concentrations were measured using enzyme-linked immunosorbent assay and normalized to the urinary creatinine concentration, and then compared among the 5 groups.
RESULTS: The urinary PGE(2) level was significantly higher in patients with brain diseases than in healthy controls, even in the patients without any OAB symptoms, and compared with patients without LUTS, a significant increase in the urinary PGE(2) was observed in patients with OAB dry or wet (P = .004 or .015, respectively). The PGF(2α) level showed a significant increase in OAB wet compared with patients without LUTS (P = .001). The urinary levels of NGF and substance P were not significantly associated with OAB as a result of this type of brain disease.
CONCLUSION: The urinary PGE(2) level was putatively elevated in patients with suprapontine brain diseases and associated with the presence of OAB. The PGF(2α) level may also be associated with OAB.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20800884     DOI: 10.1016/j.urology.2010.06.012

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  Urinary biomarkers in patients with detrusor underactivity with and without bladder function recovery.

Authors:  Sheng-Fu Chen; Yuan-Hong Jiang; Hann-Chorng Kuo
Journal:  Int Urol Nephrol       Date:  2017-08-02       Impact factor: 2.370

Review 2.  How does the urothelium affect bladder function in health and disease? ICI-RS 2011.

Authors:  L A Birder; M Ruggieri; M Takeda; G van Koeveringe; S Veltkamp; C Korstanje; B Parsons; C H Fry
Journal:  Neurourol Urodyn       Date:  2012-01-24       Impact factor: 2.696

3.  The future of research in female pelvic medicine.

Authors:  Jamie Chao; Toby C Chai
Journal:  Curr Urol Rep       Date:  2015-02       Impact factor: 3.092

4.  What is the role for biomarkers for lower urinary tract disorders? ICI-RS 2013.

Authors:  Christopher H Fry; Arun Sahai; Bahareh Vahabi; Anthony J Kanai; Lori A Birder
Journal:  Neurourol Urodyn       Date:  2014-01-16       Impact factor: 2.696

Review 5.  Management of refractory OAB in the non-neurogenic patient.

Authors:  Bassem S Wadie
Journal:  Curr Urol Rep       Date:  2014-09       Impact factor: 3.092

6.  Potential Biomarkers for Diagnosis of Overactive Bladder Patients: Urinary Nerve Growth Factor, Prostaglandin E2, and Adenosine Triphosphate.

Authors:  Yoon Seok Suh; Kwang Jin Ko; Tae Heon Kim; Hyo Serk Lee; Hyun Hwan Sung; Won Jin Cho; Munjae Lee; Kyu-Sung Lee
Journal:  Int Neurourol J       Date:  2017-09-12       Impact factor: 2.835

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.